Stock Research for ABT

Featured Broker: Ally Invest

Get the due diligence for another stock.


ABT Stock Chart & Research Data

The ABT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ABT Due diligence Resources & Stock Charts

The ABT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABT Detailed Price Forecast - CNN Money CNN View ABT Detailed Summary - Google Finance
Yahoo View ABT Detailed Summary - Yahoo! Finance Zacks View ABT Stock Research & Analysis -

Stock Analysis

TradeIdeas View ABT Trends & Analysis - Trade-Ideas Barrons View ABT Major Holders - Barrons
NASDAQ View ABT Call Transcripts - NASDAQ Seeking View ABT Breaking News & Analysis - Seeking Alpha
Spotlight View ABT Annual Report - OTC Report View ABT OTC Short Report -
TradeKing View ABT Fundamentals - TradeKing Charts View ABT SEC Filings - Bar Chart
WSJ View Historical Prices for ABT - The WSJ Morningstar View Performance/Total Return for ABT - Morningstar
MarketWatch View the Analyst Estimates for ABT - MarketWatch CNBC View the Earnings History for ABT - CNBC
StockMarketWatch View the ABT Earnings - StockMarketWatch MacroAxis View ABT Buy or Sell Recommendations - MacroAxis
Bullish View the ABT Bullish Patterns - American Bulls Short Pains View ABT Short Pain Metrics -

Social Media Mentions

StockTwits View ABT Stock Mentions - StockTwits PennyStocks View ABT Stock Mentions - PennyStockTweets
Twitter View ABT Stock Mentions - Twitter Invest Hub View ABT Investment Forum News - Investor Hub
Yahoo View ABT Stock Mentions - Yahoo! Message Board Seeking Alpha View ABT Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ABT - Insider Cow View Insider Transactions for ABT - Insider Cow
CNBC View ABT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABT - OTC Markets
Yahoo View Insider Transactions for ABT - Yahoo! Finance NASDAQ View Institutional Holdings for ABT - NASDAQ

Stock Charts

FinViz View ABT Stock Insight & Charts - StockCharts View ABT Investment Charts -
BarChart View ABT Stock Overview & Charts - BarChart Trading View View ABT User Generated Charts - Trading View

Latest Financial News for ABT

5 Biggest Medtech Stocks -- Are They Buys?
Posted on Friday December 14, 2018

These medtech giants rule the industry. But are any of them great picks for long-term investors?

Abbott Raises Quarterly Dividend 14%, Increasing Payouts for 47 Straight Years
Posted on Friday December 14, 2018

ABBOTT PARK, Ill., Dec. 14, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. ...

Do Analysts See Any Upside for DaVita Stock?
Posted on Friday December 14, 2018

Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”

Understanding Abbott Laboratories’ Operational Performance
Posted on Thursday December 13, 2018

In the latest quarter, Abbott Laboratories’ (ABT) selling, general, and administrative expenses rose YoY (year-over-year) to $2.38 billion from $2.11 billion due to its Alere acquisition and expenditure for expanding the company’s different businesses. Meanwhile, its R&D (research and development) expenses rose YoY to $574.0 million from $568.0 million due to the Alere acquisition and increased cardiovascular and neuromodulation spending. It is expected to have R&D expenses of $2.25 billion and $2.36 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $1. ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.